Home / Technology & Devices

Technology & Devices

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

LAUSANNE, Switzerland–(BUSINESS WIRE)–Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology. The test will measure the response in patients with …

Read More »

New Technologies Offer the Possibility of Identifying Cancer from a Single Blood Draw

ALEXANDRIA, Va. – Two blood tests show promise as screening tools to identify patients with cancer of different types and across different stages. Results from the two approaches will be presented at the ASCO Breakthrough meeting October 11-13, 2019 in Bangkok. While the technology and science behind the two tests to be …

Read More »

GE Healthcare and Theragnostics Enter Global Commercial Partnership for Late Stage PSMA Diagnostic for Prostate Cancer

LONDON, Oct. 9, 2019 /PRNewswire/ — GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations and as and when approval …

Read More »

Medtronic Receives FDA Breakthrough Device Designation for Developing Stent Graft System to Treat Thoracoabdominal Aortic Aneurysm

DUBLIN, Oct. 08, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Valiant® TAAA Stent Graft System for minimally invasive repair of thoracoabdominal aortic aneurysm (TAAA). A TAAA is a complex condition causing a bulging of …

Read More »

Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic Tests

San Diego, California, Hilden, Germany and Germantown, Maryland – October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. The …

Read More »

Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of an expert panel consensus statement that includes appropriate use criteria for DecisionDx®-Melanoma in patients with cutaneous melanoma. The study was published in the peer-reviewed …

Read More »

Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

NORTH BILLERICA, Mass. & NEW YORK–(BUSINESS WIRE)–Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial …

Read More »

Cepheid Receives FDA Clearance for Xpert BCR-ABL Ultra Test for Monitoring Disease Burden in CML Patients

SUNNYVALE, Calif., Oct. 2, 2019 /PRNewswire/ — Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden in patients with Chronic Myeloid Leukemia (CML). Xpert BCR-ABL Ultra, an in vitro diagnostic test, is the first FDA-cleared test …

Read More »

Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligence

Basel, and Redmond, October 1, 2019 – Novartis today announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The new lab aims to bolster Novartis AI capabilities from research through commercialization and …

Read More »

Numab and Eisai Enter Global Research and Option Agreement to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

TOKYO & ZURICH–(BUSINESS WIRE)–Numab Therapeutics AG (Numab) today announced the initiation of a partnership with Eisai, Co., Ltd (Eisai), under a research and option agreement, to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH™ platform. Under the terms of the agreement, Eisai has the option …

Read More »